What You Should Know:
The AI in Drug Discovery market in terms of revenue was estimated to be worth $600M in 2022 and is poised to reach $4B by 2027, growing at a CAGR of 45.7% from 2022 to 2027 according to a new report published by MarketsandMarkets™. The report cites the growing need to curb the drug discovery cost & reduce the overall time taken in this process, the rising adoption of cloud-based applications and services, and the impending patent expiry of blockbuster
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
3 Ways Government Can Catalyze Biomedical Innovation
What You Should Know:
Deloitte has published some new research about how government can advance biomedical innovation and improve public health.The report shares insights from various government leaders and biomedical industry experts on lessons learned from the COVID-19 pandemic, what’s driving innovation, the challenges and opportunities in partnerships, and the government’s role in sustaining the biomedical industry.
Understanding How the Government Can Catalyze Biomedical
Read More
Q/A: IQVIA’s Global Lead Talks Unlocking AI for Drug Repurposing
In an interview with HIT Consultant, Nathan Sommerford, Global Lead for Drug Discovery and Development, IQVIA talks how unlocking artificial intelligence (AI) in drug repurposing is transforming pharma and biotech companies.
What are some of the challenges and problems associated with drug discovery “from scratch”?
Nathan Sommerford, Global Lead for Drug Discovery and Development, IQVIA: In the traditional drug discovery and development paradigm, it can cost up to $1.8 billion and
Read More
M&A: ArisGlobal Acquires SPORIFY to Expand Regulatory Solutions
What You Should Know:
ArisGlobal, a provider of life sciences software acquires SPORIFY, the trusted substances, products, organizations and referentials (SPOR) data harmonization technology solution for five of the world’s top 20 largest pharmaceutical companies. Financial details of the acquisition were not disclosed.With its second acquisition in the last 90 days, ArisGlobal is prioritizing the development of an open architecture that enables an interconnected life sciences ecosystem.The
Read More
Flatiron Health Launches Integrated RWE Solutions for Oncology
What You Should Know:
Building upon over a decade of experience providing high-quality, real-world oncology data, Flatiron Health has announced the expansion of their real-world evidence (RWE) offerings to include analytic, scientific, and consultative services, leveraging the high-quality foundational real-world data (RWD) assets that the company is well known for.Flatiron’s new Integrated RWE Solutions will include data and end-to-end services to provide a more flexible and fit-for-purpose
Read More
Datavant, AWS Partner to Generate Clinical and Patient Insights
What You Should Know:
Datavant, a provider helping organizations securely connect health data, announces that it is working with Amazon Web Services (AWS) to help healthcare and life sciences customers accelerate their ability to manage and optimize clinical and patient insights.Pharmaceutical companies, healthcare providers, research institutions, and healthcare technology customers can now access Datavant’s cutting-edge data de-identification technology in AWS, connect
Read More
Genemod Raises $4.5M to Expand Central Research Platform for Biopharma Companies
What You Should Know:
Genemod, a cloud-based workspace collaboration software for biopharma R&D teams, today announced it raised $4.5 million in seed funding, co-led by defy.vc and LDV Partners, with participation from Dolby Family Ventures and Vulcan/Cercano Ventures.Genemod digitizes data capture and workflows, so scientists can collaborate easily across an organization to accelerate life sciences R&D.
Digitize Research Workflows in Minutes
Legacy R&D software
Read More
Cowen Healthcare Raises $556M Fund to Invest in Life Sciences Companies
What You Should Know:
Cowen Healthcare Investments announced the successful close of Cowen Healthcare Investments IV ("CHI IV" or the "Fund") with total committed capital of $555.6M. CHI IV will invest primarily in mid to late-stage life sciences opportunities.Led by Kevin Raidy, Tim Anderson, and Robert Sine, Cowen Healthcare Investments supports innovation in the healthcare sectors, with a particular focus on biopharma, diagnostics, and digital health.Since its founding in 2012, the CHI
Read More
UC Berkeley Bio Track Helps Faculty Launch Biotech Startups
What You Should Know:
Berkeley SkyDeck, the global hub for entrepreneurship and a leading accelerator, today announced that it has welcomed the first three companies for its new SkyDeck LSEC Bio Track: AsparaGlue, Editpep, and MZR Neurotech.The inaugural track, created in partnership with the UC Berkeley Life Sciences Entrepreneurship Center (LSEC) through LSEC’s new Venture Grant Program, will assist the UC Berkeley faculty-led teams to launch their own biotech and life sciences
Read More
ODAIA Secures $25M for AI-Driven Commercial Insights Platform for Pharma
What You Should Know:
ODAIA, developers of MAPTUAL, an AI-powered commercial insights SaaS platform for pharmaceutical companies, announced it raised an oversubscribed $25 Million Series B financing round, led by Threshold Ventures and co-led by Monograph Capital. Wittington Ventures also joined, with participation from existing investors Flint Capital, BDC Capital, StandUp Ventures and Graphite Ventures. Emily Melton, Managing Partner of Threshold Ventures and Charles Conn, co-founder and
Read More
